These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 19095213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR, FAST Investigator Group.
    Clin Infect Dis; 2005 Jun 01; 40(11):1601-7. PubMed ID: 15889357
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
    Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL.
    Pharmacotherapy; 2008 Dec 01; 28(12):1471-82. PubMed ID: 19025428
    [Abstract] [Full Text] [Related]

  • 5. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere SL, Kitt MM, Corey GR, FAST 2 Investigator Group.
    Antimicrob Agents Chemother; 2006 Mar 01; 50(3):862-7. PubMed ID: 16495243
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G.
    Int J Infect Dis; 2005 Sep 01; 9(5):251-61. PubMed ID: 16099700
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY, Calhoun JH, Thomas TS, Wirtz ED.
    J Antimicrob Chemother; 2009 Feb 01; 63(2):357-60. PubMed ID: 19060292
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N.
    J Drugs Dermatol; 2007 Jan 01; 6(1):97-103. PubMed ID: 17373167
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug 01; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 12. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN, Shively EH, Polk HC.
    Am J Surg; 2005 Apr 01; 189(4):425-8. PubMed ID: 15820454
    [Abstract] [Full Text] [Related]

  • 13. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS, Sorensen SV, Liu LZ, Itani KM.
    Ann Pharmacother; 2006 Jun 01; 40(6):1017-23. PubMed ID: 16720705
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
    Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR.
    J Antimicrob Chemother; 2012 Jun 01; 67(6):1496-502. PubMed ID: 22416054
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H, 307 Study Group.
    J Antimicrob Chemother; 2008 Sep 01; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
    Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ.
    Int J Clin Pract; 2008 Sep 01; 62(9):1455-64. PubMed ID: 18662172
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E, Sorensen S, Levrat F, Besnier JM, Dupon M, Guery B, Duttagupta S.
    Med Mal Infect; 2009 May 01; 39(5):330-40. PubMed ID: 19304423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.